Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FBP1 | P09467 | 13/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.43 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10686743 | 0.85 | GPR35 (0.46) | FBP1GPR35MEN1ALDH1A1LMNA | |
| SCHEMBL3138102 | 0.85 | GPR35 (0.46) | FBP1GPR35MEN1ALDH1A1LMNA | |
| SCHEMBL29701589 | 0.82 | GPR35 (0.46) | GPR35MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL7646920 | 0.82 | GPR35 (0.46) | GPR35MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL28137614 | 0.81 | FBP1 (0.54) | FBP1FFAR1GPR35TSHR | |
| SCHEMBL4714927 | 0.81 | FFAR1 (0.59) | FFAR1FFAR4MEN1ALDH1A1KMT2A | |
| SCHEMBL5696593 | 0.80 | MAPT (0.43) | MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL15511866 | 0.79 | ALDH1A1 (0.43) | FBP1GPR35MEN1ALDH1A1LMNA | |
| SCHEMBL30625901 | 0.79 | ALDH1A1 (0.43) | GPR35MEN1ALDH1A1LMNAKMT2A | |
| SCHEMBL27708037 | 0.79 | MAPT (0.43) | GPR35MEN1ALDH1A1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106534-A1 | NOVEL HETEROCYCLIC CARBOXAMIDES AS M1 AGONISTS | H. LUNDBECK A/S (DK) | 2009-09-03 | — | — | WO | disclosed |
| EP-1499606-B8 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER (US) | 2006-08-30 | — | — | EP | disclosed |
| EP-1673367-A1 | FUSED LACTAM COMPOUNDS | Pfizer, Inc. (US) | 2006-06-28 | — | — | EP | disclosed |
| WO-2005035523-A1 | FUSED LACTAM COMPOUNDS | PFIZER JAPAN INC. (JP) | 2005-04-21 | — | — | WO | disclosed |
| EP-1499606-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2005-01-26 | — | — | EP | disclosed |
| US-6713490-B2 | 6-(2-(4-(3-FLUOROPHENYL)-4-HYDROXY-1-PIPERIDINYL)-1-HYDROXY -ETHYL)-3,4-DIHYDRO-2(1H)-QUINOLINONE; REDUCED INHIBITORY ACTIVITY AT HERG (HUMAN ETHER-A-GO-GO RELATED GENE) POTASSIUM CHANNEL | PFIZER, INC. | 2004-03-30 | — | — | US | disclosed |
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | KAWAMURA MITSUHIRO (JP) | 2003-11-20 | — | — | US | disclosed |
| WO-2003091241-A1 | 3, 4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUNDS AS NR2B RECEPTOR ANTAGONISTS | PFIZER JAPAN INC. (JP) | 2003-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216430-A1 | 3, 4-dihydroquinolin-2(1H)-one compounds as NR2B receptor antagonists | GRIN3B, GRIN1, GRIN2A | FBP1 4174/4885FFAR1 275/4885FFAR4 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.